ZYME Zymeworks Inc

  1. Stocks
  2. Healthcare
  3. NYSE: ZYME

Price (delayed)

$8.87

Market cap

$620.92M

P/E Ratio

2.74

Dividend/share

N/A

EPS

$3.24

Enterprise value

$552.83M

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of ...

Highlights
Zymeworks's net income has surged by 192% YoY and by 10% QoQ
ZYME's EPS has soared by 189% year-on-year and by 11% since the previous quarter
The company's equity has surged by 136% YoY but it fell by 5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zymeworks.com
Peers: OMGA

Key stats

What are the main financial stats of ZYME
Market
Shares outstanding
70M
Market cap
$620.92M
Enterprise value
$552.83M
Valuations
Price to earnings (P/E)
2.74
Price to book (P/B)
1.42
Price to sales (P/S)
1.36
EV/EBIT
2.51
EV/EBITDA
2.34
EV/Sales
1.2
Earnings
Revenue
$461.58M
EBIT
$220.4M
EBITDA
$236.66M
Free cash flow
$192.64M
Per share
EPS
$3.24
Free cash flow per share
$2.73
Book value per share
$6.26
Revenue per share
$6.54
TBVPS
$7.6
Balance sheet
Total assets
$556.37M
Total liabilities
$132.02M
Debt
$26.25M
Equity
$424.34M
Working capital
$301.79M
Liquidity
Debt to equity
0.06
Current ratio
5.14
Quick ratio
4.98
Net debt/EBITDA
-0.29
Margins
EBITDA margin
51.3%
Gross margin
100%
Net margin
44.5%
Operating margin
44.4%
Efficiency
Return on assets
34.1%
Return on equity
44.6%
Return on invested capital
68.5%
Return on capital employed
45.6%
Return on sales
47.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZYME stock price

How has the Zymeworks stock price performed over time
Intraday
0.57%
1 week
6.35%
1 month
26.9%
1 year
14.9%
YTD
12.85%
QTD
39.91%

Financial performance

How have Zymeworks's revenue and profit performed over time
Revenue
$461.58M
Gross profit
$461.58M
Operating income
$204.76M
Net income
$205.24M
Gross margin
100%
Net margin
44.5%
Zymeworks's net income has surged by 192% YoY and by 10% QoQ
ZYME's operating income has surged by 189% year-on-year and by 9% since the previous quarter
The operating margin has soared by 106% YoY and by 6% from the previous quarter
The company's net margin has surged by 106% YoY and by 7% QoQ

Growth

What is Zymeworks's growth rate over time

Valuation

What is Zymeworks stock price valuation
ZYME P/E details
P/E
2.74
P/B
1.42
P/S
1.36
EV/EBIT
2.51
EV/EBITDA
2.34
EV/Sales
1.2
ZYME's EPS has soared by 189% year-on-year and by 11% since the previous quarter
The P/E is 12% less than the last 4 quarters average of 3.1
The company's equity has surged by 136% YoY but it fell by 5% QoQ
ZYME's P/B is 53% below its 5-year quarterly average of 3.0 but 29% above its last 4 quarters average of 1.1
The stock's price to sales (P/S) is 96% less than its 5-year quarterly average of 33.5 but 13% more than its last 4 quarters average of 1.2
Zymeworks's revenue has increased by 3.1% from the previous quarter

Efficiency

How efficient is Zymeworks business performance
Zymeworks's ROA has soared by 157% YoY
Zymeworks's return on equity has surged by 146% YoY but it has decreased by 4.5% QoQ
ZYME's ROIC has soared by 136% year-on-year but it is down by 10% since the previous quarter
ZYME's ROS has soared by 106% year-on-year and by 7% since the previous quarter

Dividends

What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZYME.

Financial health

How did Zymeworks financials performed over time
Zymeworks's total assets has surged by 85% YoY but it has decreased by 8% QoQ
The quick ratio has surged by 66% year-on-year and by 20% since the previous quarter
The company's debt is 94% lower than its equity
The company's equity has surged by 136% YoY but it fell by 5% QoQ
The debt to equity has dropped by 65% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.